Evidence map›Paper›PMID 40604940›Full record

ArticleBMC complementary medicine and therapies2025

PLGA-based herb Toosendanin delivery system for efficient therapy of oral squamous cell carcinoma.

Lingling Chen, Cheng Feng, Zhenyu Shi, Jianzhe Wang, Tao Wang, Yibing Wang, Lisong Lin, Ye Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lingling Chen *Fujian Key Laboratory of Oral Diseases & Stomatological Key Lab of Fujian College and University, School and Hospital of Stomatology, Fujian Medical University, Fuzhou, 350002, Fujian Province, China.
Cheng Feng *Fujian Key Laboratory of Oral Diseases & Stomatological Key Lab of Fujian College and University, School and Hospital of Stomatology, Fujian Medical University, Fuzhou, 350002, Fujian Province, China.
Zhenyu ShiFujian Key Laboratory of Oral Diseases & Stomatological Key Lab of Fujian College and University, School and Hospital of Stomatology, Fujian Medical University, Fuzhou, 350002, Fujian Province, China.
Jianzhe WangFujian Key Laboratory of Oral Diseases & Stomatological Key Lab of Fujian College and University, School and Hospital of Stomatology, Fujian Medical University, Fuzhou, 350002, Fujian Province, China.
Tao WangFujian Key Laboratory of Oral Diseases & Stomatological Key Lab of Fujian College and University, School and Hospital of Stomatology, Fujian Medical University, Fuzhou, 350002, Fujian Province, China.
Yibing WangFujian Key Laboratory of Oral Diseases & Stomatological Key Lab of Fujian College and University, School and Hospital of Stomatology, Fujian Medical University, Fuzhou, 350002, Fujian Province, China.
Lisong LinDepartment of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350004, Fujian Province, China. dr_lls@fjmu.edu.cn.
Ye WuFujian Key Laboratory of Oral Diseases & Stomatological Key Lab of Fujian College and University, School and Hospital of Stomatology, Fujian Medical University, Fuzhou, 350002, Fujian Province, China. wuye@fjmu.edu.cn.

Funding

Fujian Provincial Department of Finance 22SCZZX010
6 · The paper itself

Abstract

Oral squamous cell carcinoma (OSCC) is a significant public health issue worldwide. Conventional chemotherapeutic agents do not adequately meet the treatment demands because of their low efficacy and adverse side effects. Toosendanin (TSN) is a natural extract with potential anticarcinogenic activity. Nonetheless, its clinical application is constrained by its poor water-solubility and limited bioavailability. Therefore, we prepared TSN-loaded poly (lactic-co-glycolic acid) nanoparticles (TSN-PLGA NPs) to improve the water-solubility of TSN and potentially further enhance its bioavailability. TSN-PLGA NPs were synthesized and characterized, and we showed their exceptional properties for sustained release in vitro. TSN-PLGA NPs exhibited cytotoxic effects against OSCC cells, potentially inhibiting proliferation and promoting apoptosis by inducing cell-cycle arrest in the S-phase at low concentrations. RNA-sequencing analysis revealed the potential regulation of OSCC cell viability by TSN-PLGA NPs through signaling pathways such as JAK/STAT and PI3K-Akt. Furthermore, animal models provided evidence of the in vivo antitumor activity of TSN-PLGA NPs, with no observable side effects in nude mice, which indicated potential biocompatibility. Consequently, TSN-PLGA NPs may be a promising chemotherapy candidate for OSCC treatment.

Indexed as

Carcinoma, Squamous CellMouth NeoplasmsPolylactic Acid-Polyglycolic Acid CopolymerAnimalsCell Line, TumorDrug Delivery SystemsHumansMiceMice, NudeNanoparticlesPolylactic Acid-Polyglycolic Acid CopolymerEPR effectNanomedicineOral squamous cell carcinomaPLGAToosendanin

Identifiers

PMID40604940
PMCPMC12220433

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.